Preoperative CA 19-9 predicts disease progression in colorectal peritoneal metastases treated with CRS/HIPEC

Elevated levels of CA 19-9, a tumor marker, were found to be associated with decreased progression-free survival (PFS) in patients with colorectal peritoneal metastases (CRPM) treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). The study, which included 279 patients, showed that patients with elevated CA 19-9 had a much worse PFS rate compared to those with normal levels. CA 19-9 was independently predictive of worse PFS in patients who underwent upfront CRS/HIPEC. However, further prospective studies are needed to confirm this association.